SUMMARY
INTRODUCTION
Reproductive disorders are common in adult patients from both sexes with end-stage renal disease (1) . It has been reported that in female patients hypothalamichypophysial regulation is disrupted due to increase in growth hormone and prolactin levels as a result of uremia, and that libido decreases in women as in men (2) (3) (4) (5) (6) (7) .
In women with chronic renal failure (CRF), since the LH surge stimulated by estrogen does not happen, anovulation, menstrual disorders and infertility develops (8) . Furthermore, in uremic patients even if gonadotropin levels increase following ovarian stimulation with clomiphene, there is no increase in estrogen levels. This supports the existence of ovarian resistance against stimulation (2) . Studies have shown that 50-100% of patients have amenorrhea (9) , and among the patients that have periods 50 to 80% have hypermenorrhea, menometrorrhagia, or oligomenorrhea (5, 10, 11) . In addition, while amenorrhe was detected in women with high prolactin, regular menstruation was reported in women with the lowest level of prolactin (5) .
Normal menstrual cycles and ovulation might be seen with the start of hemodialysis (11, 12) .
As the length of life increase with the emerging treatment options, especially in women, we started to face of the problems related to reproductive system more frequently.
In this study, we aimed to investigate the mechanism underlying the menstrual disorders by looking at menstrual histories of chronic renal failure patients undergoing hemodialysis, along with hormone levels and other biochemical factors.
MATERIALS AND METHODS
In our study, 30 patients undergoing hemodialysis (patient group), 30 control patients (control group) and a total of 60 patients that agreed to participate in the study were included. Before the study was started approval was provided by the ethics committee of SSK Bicarbonate dialysis was performed in all the patients in the study and during the dialysis low-molecular-weight heparin (Fragminin, Fraxiparine) was used for the prevention of clotting of the blood. Phos-ex 3X1 or 3x2 oral tablets, Vitamin D3, B-complex vitamins were used as calcium supplements and in order to bind phosphorus, folic acid was used in megaloblastic anemia and erythropoietin was used in patients that have a hematocrit level less than 30%, and patients with albumin levels below 4g/dL were receiving essential amino acids. Hemodialysis and control groups were compared in terms of all these parameters.
In the biochemistry laboratory of SSK Istanbul Teaching Hospital urea, creatinine and electrolytes were analysed using Olympus AU 5223 automated analysis device, and complete blood count analysis was performed in the Sysmex SE-9000 device models. FSH, LH, TSH and prolactin levels were evaluated in ACS 180 analysis device using electrochemiluminescence immunoassay technique. References of the biochemical laboratory were used for the interpretation of the test results. In addition, during the 8th day of menses the endometrial thickness of all the patients undergoing hemodialysis and the control group was measured by pelvic ultrasound and compared between groups.
Hemodialysis patients were divided into four groups as amenorrheic, oligomenoreic, menorrhagic and regular according to their forms of menstruation. Hormonal, hematologic and biochemical values of patients from these four groups were compared. In this study, the patients were also divided into two groups as patients that have amonerrhea or not following the dialysis and they were compared with respect to hormonal parameters. Among the patient group in all the patients with menstrual irregularities, spontaneous menstruation was waited to perform hormonal and biochemical blood tests and no treatment was started in none of the patients.
In our study SPSS 9.0 (SPSS Inc., Chicago, Illinois) software package was used for the statistical analysis. For comparison of patient and control groups Student's t-test and MannWhitney U test were performed. Kruskal-Wallis test was used for comparison of more than two groups.
RESULTS

Demographic data and comparisons of 30 hemodialysis
and 30 control patients a total of 60 patients are shown in GRAV‹DA (median (min-max)) 1,00 (0,00-4,00) 2,00 (0,00-5,00) 0,815 PAR‹TE (median (min-max)) 1,00 (0,00-4,00) 1,00 (0,00-4,00) 0,981 ABORTUS (median (min-max)) 0,00 (0,00-2,00) 0,00 (0,00-2,00) 0,139 KÜRETAJ (median (min-max)) 0,00 (0,00-2,00) 0,00 (0,00-3,00) 0,061 of the patients amenorrhea continued (13) . Morley et al reported that among the 12 hemodialysis patients 7 (58%) of the patients developed amenorrhea; in 4 (57%) patients amenorrhea continued after hemodialysis, and in 3 (42%) patients menses returned (11) . In our study in line with the literature we also showed that in a total of 30 hemodialysis patients14 (47%) of them developed amenorrhea after receiving the dialysis program and found that this lasted for an average of 12 months. With the hemodialysis therapy, amenorrhea seemed to disappear in the majority of these patients. During the study, only 5 of these patients (36%) amenorrhea persisted, and in 57% of the patients regular menstruation was seen, 23% of them had oligomenorrhea, 17% of them had amenorrhea, and 3% had menometrorrhagia.
Menstrual changes and blood hormone levels might axis, studies have shown that LH levels were higher in premenopausal women with CRF (5, 11, 12, 14) . Both the metabolic clearance of LH decreases and production increases. The reply to the LHRH stimulation is delayed, but the responses might be normal or above normal.
A limited number of studies suggest that in uremic female patients pulsatile LH secretion does not happen (15, 16) . Diurnal pulsatile LH release, preovulatuar high levels of LHRH and as a result LH surge necessary for ovulation could not be monitored in most of the patients (17, 18) . While there are studies showing normal levels of FSH in uremic patients as in follicular and luteal phases of normal women (11) , there are other studies reported high levels of FSH (5, 15) . In contrast to primary ovarian failure, the decrease in FSH / LH ratio indicates disorder of hypothalamic-pituitary regulation. Many factors that might lead to all these changes were investigated and are still being investigated (17) . In accordance with the literature we found significantly higher levels of LH in hemodialysis patients compared to the control group (p <0.05).
Moreover, even though FSH levels were higher in hemodialysis patients compared to the control group there was no statistically significant difference (p> 0.05).
Even though estradiol levels in hemodialysis patients were detected lower than the control group this difference was not statistically significant (p> 0.05).
Similarly, Lim et al have found in their study including 24 patients that estradiol levels in the follicular phase were close to the values of the control group (19) .
However, several studies including a large number of cases reported that estradiol levels are significantly lower compared to the control group (14, 15, 20) .
Another significant change in CRF patients is the hyperprolactinemia that disrupts ovarian function suppressing hypothalamus-pituitary-ovarian at many stages. Increase in prolactin levels in uremic patients since the 1970s (21) . Sievertsen et al. (4) found high plasma prolactin levels in 70% of the 73 hemodialysis patients. When the pharmacokinetics of prolactin in these patients were investigated, the extension of halflife was found associated with increased production of the pituitary along with longer clearance time from the circulation. Increased production rate, on the other hand, was shown to be associated with unresponsiveness of lactotrophic cells to the inhibitory effect of dopamine and was shown by longer duration of clearence of prolactin from the circulation during the dopamine infusion of 4 micrograms/kg x minute (4) . In our study, we found high levels of prolactin in 22 (73%) patients. In addition, when the patient and control groups were compared for the prolactin levels, we have seen that prolactin levels were 3-fold higher in hemodialysis patients. Even though prolactin levels were high in 73% of the patients, galactorrhea was found only in 13% of them. Similarly, in the literature galactorrhea was reported in 0% to 40% of hemodialysis patients (10) .
Another issue questioned in patients with CRF is the cause of frequent amenorrhea.In our study, when the as the prolactin levels increase (22) .
Matuszkiewicz-Rowinska et al (5) found that LH and FSH levels were significantly higher in dialysis patients compared to the other groups. In addition, they have reported that patients with amenorrhea had significantly lower levels of serum estradiol (5) . As it has been shown hyperprolactinemia is an important cause of menstrual disorders in hemodialysis patients.
In our study we used endometrial thickness measurements as an indicator of ovarian hormones.
As it is known with the direct influence of ovarian hormones, estrogen and progesterone, cyclic changes in the endometrium occur as they are easily recognizable with the sonoraphy. In particular estrogen has trophic effect on the endometrium. During the proliferative phase the thickness of the normal endometrium varies between 4-8 mm (23) . In our study the endometrial thickness in the patient group was 6.52 +2.13 mm and in the control group it was 6,58+1,59 mm (p> 0.05). 
